About Perceive Bio
Perceive Bio is a Healthcare company based in San Francisco (United States) founded in 2021 by Anne Rubin. Developer of therapeutics to treat diabetes and eye diseases. Perceive Bio has raised $78 million across 1 funding round from investors including Johnson & Johnson Innovation, Deerfield and Retinal Degeneration Fund. Its chief executive, as recorded, is K Angela Macfarlane. Perceive Bio offers products and services including Pipeline Assets, Therapeutics for Dry AMD, and Neuroprotection Therapies. Its focus areas include Life Sciences, Diabetes, Drugs and Diabetic Retinopathy. Its legal entity is Perceive Biotherapeutics, Inc. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Perceive Bio was founded in 2021 and is headquartered in San Francisco, United States. Therapeutics are developed by the company to address diabetes and various eye diseases. A pipeline of drugs is being advanced for conditions including retinal degeneration, dry age-related macular degeneration, neuroprotection, and central nervous system disorders. Operations focus on biotechnology research and drug development in the healthcare sector.
- Headquarters San Francisco, United States
- Founders Anne Rubin
- SectorsHealthcare
- Email••••••••
- Website perceivebio.com
- Social LinkedIn
- Legal Name Perceive Biotherapeutics, Inc.
- Total Equity Funding$78M (USD)
in 1 rounds
- Latest Funding Round$78M (USD), Series B
Jan 2023
- InvestorsJohnson & Johnson Innovation
& 4 more
Products & Services of Perceive Bio
Perceive Bio offers a comprehensive portfolio of products and services, including Pipeline Assets, Therapeutics for Dry AMD, and Neuroprotection Therapies.
Develops treatments for dry AMD and retinal neuroprotection via biological innovations
Targets dry age-related macular degeneration to prevent vision loss
Focuses on protecting retinal cells from degeneration through research
Funding Insights of Perceive Bio
Perceive Bio has successfully raised a total of $78M through 1 strategic funding round. The most recent funding activity was a Series B round of $78 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78M
- Total Rounds 1
- Last Round Series B — $78M
- First Round $78M
(Jan 2023)
- Investors Count 5
All 1 funding rounds of Perceive Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | $78M | Series B | – | Johnson & Johnson Innovation |
5 investors in total: 5 institutional.
Investors in Perceive Bio
Perceive Bio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Johnson & Johnson Innovation, Deerfield and Retinal Degeneration Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Investments are focused on retinal degeneration therapeutic solutions. | retinaldegenerationfund.org | Raleigh, United States | ||
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
| jnjinnovation.com | ||||
Offers flexible capital and partnerships to companies in life sciences sectors. | braidwell.com |
Investor details for Perceive Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Perceive Bio
9 people are tracked at Perceive Bio (7 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Anne Rubin | Co-Founder | Leadership |
K Angela Macfarlane | CEO | Leadership |
Anne Fung | Chief Medical Officer | Leadership |
Ranjit Ahluwalia | Chief Financial Officer | Leadership |
Laura Adamson | Vice President Gene Therapy Development | Leadership |
Paulius O. | Vice President Clinical Operations | Leadership |
Dainius MacIkenas | Director Of Development | Leadership |
Adrienne Porzycki | Clinical Program Manager AMD | Team |
Risa Broyer | Senior Scientist | Team |
Complete people profiles for Perceive Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Perceive Bio
2 dated milestones of Perceive Bio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Perceive Bio is founded.
- Funding First funding round of $78.0M.
Competitors of Perceive Bio
Perceive Bio has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Perceive Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Perceive Bio (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Perceive Bio
Complete news archive for Perceive Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perceive Bio
Perceive Bio was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Perceive Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
K Angela Macfarlane is the CEO of Perceive Bio, as recorded in our data.
Perceive Bio is a funded company, having raised a total of $78M across 1 funding round to date. The company's 1st funding round was a Series B of $78M, raised on Jan 2023.
Perceive Bio was founded in 2021 and is headquartered in San Francisco, United States. Therapeutics are developed by the company to address diabetes and various eye diseases. A pipeline of drugs is being advanced for conditions including retinal degeneration, dry age-related macular degeneration, neuroprotection, and central nervous system disorders. Operations focus on biotechnology research and drug development in the healthcare sector.
Perceive Bio's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Perceive Bio offers Pipeline Assets, Therapeutics for Dry AMD, and Neuroprotection Therapies.
Perceive Bio has 5 investors. Key investors include Johnson & Johnson Innovation, Deerfield, Retinal Degeneration Fund, Catalio Capital Management, and Braidwell.
Perceive Bio operates through Perceive Biotherapeutics, Inc..